Park, Matthew D.
Reyes-Torres, Ivan
LeBerichel, Jessica
Hamon, Pauline
LaMarche, Nelson M.
Hegde, Samarth
Belabed, Meriem
Troncoso, Leanna
Grout, John A.
Magen, Assaf http://orcid.org/0000-0001-5473-274X
Humblin, Etienne
Nair, Achuth
Molgora, Martina
Hou, Jinchao
Newman, Jenna H.
Farkas, Adam M.
Leader, Andrew M.
Dawson, Travis
D’Souza, Darwin
Hamel, Steven
Sanchez-Paulete, Alfonso Rodriguez
Maier, Barbara http://orcid.org/0000-0002-7359-6576
Bhardwaj, Nina http://orcid.org/0000-0003-1865-4187
Martin, Jerome C. http://orcid.org/0000-0003-0068-8776
Kamphorst, Alice O.
Kenigsberg, Ephraim http://orcid.org/0000-0002-4107-3295
Casanova-Acebes, Maria http://orcid.org/0000-0002-5790-1163
Horowitz, Amir
Brown, Brian D. http://orcid.org/0000-0002-3670-8778
De Andrade, Lucas Ferrari
Colonna, Marco http://orcid.org/0000-0001-5222-4987
Marron, Thomas U. http://orcid.org/0000-0001-5903-8191
Merad, Miriam http://orcid.org/0000-0002-4481-7827
Article History
Received: 30 June 2022
Accepted: 23 February 2023
First Online: 20 April 2023
Competing interests
: L.F.d.A. is a named inventor of the MIC-A therapeutic antibody in a filed patient (US20200165343A1) and has received royalty payments in relation to this therapeutic. L.F.d.A. is also co-inventor in issued patents about an α-3 domain-specific antibody. M.C. receives research support from NGM Biotechnology and Vigil Neuro, is a scientific advisory board member of NGM Biotechnology and Vigil Neuro and has a patent for TREM2 pending. M.M. serves on the scientific advisory board and holds stock from Compugen, Myeloid Therapeutics, Morphic Therapeutic, Asher Bio, Dren Bio, Nirogy, Oncoresponse, Owkin, Pionyr, OSE and Larkspur. M.M. serves on the scientific advisory board Innate Pharma, DBV and Genenta. M.M. is a named co-inventor on an issued patent for multiplex immunohistochemistry to characterize tumors and treatment responses. The technology is filed through Icahn School of Medicine at Mount Sinai and is currently unlicensed. This technology was used to evaluate tissue in this study and the results could impact the value of this technology. The remaining authors declare no competing interests.